Also, the increased risk of myocardial infarction after infections has been recognized for decades. 4 As this risk is constant for a wide variety of etiologic agents and sites of infection, it is probably reasonable to assume that the systemic inflammatory reaction, and not the specific pathogen or location, is the major determinant of this relationship. Possible contributing mechanisms are the increased inflammatory activity in atheromatous plaques and the pro-thrombotic state induced by the systemic inflammatory reaction.
In this issue of the European Journal of Preventive Cardiology, Zhao and associates from Beijing add another important piece of information. In a study of more than 7600 patients with triple vessel disease followed for a median of 7.5 years, they report that white blood cell count at admission was an independent predictor of death and major cardiovascular and cerebrovascular events during the follow-up. 5 At multivariable analysis, increased monocytes and eosinophils and decreased lymphocytes were found to be independently associated with death. The study by Zhao is important not only for the large sample size and the long followup, but also because it suggests a strong predictive value for subsequent cardiovascular events of the simplest laboratory test routinely performed in almost all patients admitted to the hospital.
The study has important limitations in terms of heterogeneity of the patient population (treated by percutaneous or surgical intervention and medical therapy, and with stable and unstable coronary artery disease -patients with active infection were also included). Also, the very important differences in the risk profile between patients experiencing events and the rest of the population are probably too wide to be neutralized by statistical adjustment. Nevertheless, there is a solid biologic rationale for the presented findings and the main results of the analysis appear convincing.
Despite instances of important progress in interventional and medical management, the prognosis of patients with coronary artery disease is still suboptimal. Data from large registries show that after an acute event, the risk of recurrent adverse events is substantial and that, despite all our current armamentarium for acute treatment and secondary prevention of coronary syndromes, roughly one in five patients with acute myocardial infarction will experience a second coronary episode within a relatively short period (5 years). 6, 7 It is now evident that the correlation between traditional cardiovascular risk factors, lifestyle, and inflammation is more complex and closer than previously thought, providing a potential opportunity for integrate treatment. 8, 9 In this context, the Zhao study not only provides an old, new tool for prognostic stratification, but also suggests the opportunity to aggressively explore the potential role of anti-inflammatory drugs as an addition to the current treatment. Despite initial disappointing results, the use of anti-inflammatory medications in patients with coronary disease has had some success It is now evident that the correlation between traditional cardiovascular risk factors, lifestyle, and inflammation is more complex and closer than previously thought.
It is probably time to take a new look at the old question of inflammation and coronary artery disease and to combine old and new tools (white blood cell count and monoclonal antibodies) with the aim of optimizing the prognosis of patients with coronary artery disease.
Indeed, in statin-treated patients, as those enrolled in the study by Zhao et al., 5 and residual inflammatory risk revealed by high CRP levels and/or raised white blood cell count, the underlying biology driving recurrent events is a persistent vascular inflammation, and consideration of further inflammation reduction is an evidence-based position supported by the effectiveness of the interleukin-1 b antibody canakinumab, as demonstrated in CANTOS. 11 The recent surge of interest in the role of inflammation in ischemic heart disease generates new intriguing questions. First, are therapeutic strategies addressing interleukin-1b the best options we can aspire to? Interleukin-1 signaling pathway represents a major target for immune modulation, because interleukin-1b activity is not confined to innate immune cells, but it is an integral component of adaptive Th1 responses. However, expanding pathogenic concepts in acute coronary syndrome (ACS) beyond the simplified view of chronic inflammation considerably widens the spectrum of therapeutic possibilities and enables a more tailored therapeutic approach that may avoid unwanted adverse effects of aggressive immunosuppression. Indeed, T-cell receptor activation signaling offers several targets for a focused immunomodulatory therapy that prevents the excess of activation of adaptive immunity without affecting its protective effects. In addition, it has been shown that the tryptophan metabolite 3-hydroxyanthranilic acid has immune regulatory properties that can be used to decrease atherosclerosis in mice by regulating T-cell-dependent inflammation and lowering plasma lipids. 12 Second, which patients might benefit from an antiinflammatory treatment? Although a large body of evidence suggests that CRP is a good biomarker for the identification of patients with residual inflammatory risk and blood cell count, as suggested by the study of Zhao et al., 5 there might be another interesting biomarker of risk in this setting: T-cell perturbation seems to identify patients with ACS at high risk of major coronary events even better than high-sensitivity CRP. Indeed, in ACS, CD4 T-cells show enhanced response to T-cell receptor stimulation and have a lower setting of the T-cell activation threshold, which promotes T-cell differentiation markedly oriented toward aggressive effector phenotypes and defective regulatory T-cells, the lymphocyte compartment able to suppress the excessive immune response. Overall, such T-cell abnormalities characterize about one-third of patients with ACS and might represent a useful biomarker per se. A change of focus from soluble markers of inflammation to markers of adaptive immunity dysregulation might prove to be rewarding in the management of patients with ACS. 13 Third, there is growing evidence that the residual risk in patients on statin treatment can be mediated by plaque erosion which is unrelated to systemic inflammation, while it might be related to an alteration of hyaluronan metabolism, resulting in local de-endothelialization and thrombus inflammation. This mechanism of coronary instability does not seem to be captured by current markers of inflammation. 14 
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